人类tiludronate的药物动力学。
文章的细节
-
引用
复制到剪贴板 -
桑塞姆LN, Necciari J, Thiercelin摩根富林明
人类tiludronate的药物动力学。
骨头。1995年11月,17(5):479 - 483年代。
- PubMed ID
-
8573422 (在PubMed]
- 文摘
-
Tiludronate是二磷酸盐广泛评估作为osteoregulator治疗代谢性骨疾病。它是高度极低和变量口服吸收类似相关化合物。大约6%的绝对生物利用度与大型国际米兰——据报道intra-subject可变性。吸收的程度在增加剂量400毫克以上时,可能会减少5倍tiludronate管理,或在2 h后,食物或奶制品。大约有90%的tiludronate必将血清白蛋白,和绑定是线性浓度范围1 - 10 mg / L。初步使用人类肝细胞体外研究没有显示任何证据tiludronate的生物转化。在肾功能正常的患者消除半衰期大约是40 - h,但在有严重肾功能损害者显著增加。肾清除率(0.7 L / h)是独立的剂量和表明肾小球滤过机制负责消除。大约50%的吸收剂量被绑定到骨头和药物的释放速率从这个网站受到骨营业额。体外实验表明tiludronate并非一种酶诱导物或抑制剂。 Drug interaction studies with the nonsteroidal agents acetylsalicylic acid, indomethacin, and diclofenac indicate that only with indomethacin was there any change in the pharmacokinetic parameters, and that these changes were minimal and unlikely to be of clinical significance. Tiludronate does not influence the pharmacokinetics of digoxin at steady state. Tiludronate appears to exhibit similar pharmacokinetic behavior to other bisphosphonates with the exception that its absolute bioavailability is significantly higher than that previously reported for clodronate and pamidronate. The impact of its pharmacokinetic properties on clinical outcome has yet to be determined.
DrugBank数据引用了这篇文章
- 药物
- 药物的相互作用Learn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
药物 交互 整合药物之间
在您的软件的交互Tiludronic酸 吲哚美辛 的血清浓度Tiludronic酸可以增加时结合消炎痛。
